Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Danish drugmaker Novo Nordisk (NOVOb.CO) missed forecasts for third-quarter profit and sales and gave a smaller than hoped growth outlook for next year, capped by a weakening dollar and slower growth of some of its best-selling drugs.
The world's biggest insulin producer, which faces intensified competition in the fast-growing diabetes market as the world faces an epidemic of type 2 diabetes tied to over-eating and lack of exercise, said it expects high single-digit percentage operating profit and sales growth next year.
http://www.reuters.com/article/2013/10/31/us-novonordisk-result-idUSBRE99U13O20131031
The world's biggest insulin producer, which faces intensified competition in the fast-growing diabetes market as the world faces an epidemic of type 2 diabetes tied to over-eating and lack of exercise, said it expects high single-digit percentage operating profit and sales growth next year.
http://www.reuters.com/article/2013/10/31/us-novonordisk-result-idUSBRE99U13O20131031